INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2029

Conditions
Ovarian Clear Cell Carcinoma
Interventions
DRUG

QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

QL1706: 5 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 2 years.

DRUG

Bevacizumab

Bevacizumab : 15 mg/kg intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 22 cycles.

DRUG

carboplatin

Carboplatin: AUC=5, intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles

DRUG

Paclitaxel

Paclitaxel: 175 mg/m\^2 intravenously every 3 weeks until disease progression or intolerable toxicity, with a maximum duration of 6 cycles

Trial Locations (1)

430000

Tongji Hospital, Wuhan

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Fudan University

OTHER

collaborator

Sun Yat-sen University Cancer Center (SUSUCC)

UNKNOWN

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

The Second Affiliated Hospital, Sun Yat-sen University

UNKNOWN

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

Renmin Hospital of Wuhan University

OTHER

collaborator

Zhejiang Provincial People's Hospital

OTHER

collaborator

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

OTHER

collaborator

Shanghai First Maternity and Infant Hospital

OTHER

collaborator

Hubei Cancer Hospital

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

Wuhan Central Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Third Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Henan Provincial People's Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Jiangsu Cancer Institute & Hospital

OTHER

collaborator

The International Peace Maternity & Child Health Hospital of China welfare institute

UNKNOWN

collaborator

Women's Hospital School Of Medicine Zhejiang University

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

lead

Tongji Hospital

OTHER